Close

DiaMedica completes enrollment in DM199 single ascending dose diabetes study

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

New Endometrial Cancer Therapy Phase-II Trial Shows Promise

The most recent trial of a new antibody drug...

Duality Looks Out For Hong Kong IPO To Finance ADC Trials

Duality Biotherapeutics from China has gone ahead and filed...

PhotonPharma Secures $2.5 Million in Seed Funding to Advance Clinical Trial for Ovarian Cancer Treatment

PhotonPharma, a cutting-edge biopharmaceutical company based in Fort Collins,...

Clinical stage biopharmaceutical company DiaMedica has completed enrollment of type 2 diabetic patients in the DM199 single ascending dose (SAD) clinical study.

The randomized study is designed to assess three dose levels each in type 2 diabetic patients. DiaMedica chairman and CEO Rick Pauls said, “Completion of the enrollment of Type 2 Diabetic patients into the SAD portion of the Phase I/II clinical study is an important milestone in our DM199 development pathway.”

The primary objective of the SAD portion of the ongoing study is acute safety, tolerability and pharmacokinetic properties for the first time in type 2 diabetic patients, in addition to the efficacy of DM199 on improving glucose control.

The top line results from the placebo-controlled, double-blinded study are expected to be available in the third quarter of 2013.

 

Latest stories